Business Context and Reporting Period
This Form 8-K Current Report was filed by BeiGene, Ltd. on September 24, 2020. The filing details a material definitive agreement entered into with Amgen Inc. regarding the restatement of a Share Purchase Agreement originally executed in October 2019 and amended in March 2020.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, or margin data. It references historical transaction data from January 2, 2020, where BeiGene issued 206,635,013 ordinary shares (15,895,001 ADSs) to Amgen for aggregate gross proceeds of approximately $2.78 billion. The transaction price was $13.45 per ordinary share or $174.85 per ADS, representing approximately 20.5% of the Company's then-outstanding share capital.
Material Changes
On September 24, 2020, BeiGene and Amgen restated the Second Amendment to the Share Purchase Agreement. Key changes include:
- Direct Purchase Option: Amgen now holds an option to subscribe for additional shares to maintain an ownership stake of approximately 20.6% of BeiGene's outstanding share capital.
- Exercise Conditions: The option is exercisable monthly only if Amgen's ownership falls below 20.4% due to dilution from BeiGene's equity incentive plans.
- Shareholder Approval: The option is subject to annual approval by BeiGene's independent shareholders.
- HKEx Waiver: The Stock Exchange of Hong Kong Limited granted a waiver from specific listing rules regarding the Direct Purchase Option, allowing BeiGene to discontinue a prior review process.
Outlook, Risks, and Contingencies
Shareholder Approval Requirement: The Restated Second Amendment and the issuance of Additional Shares are contingent upon approval by a majority vote of BeiGene's shareholders, excluding Amgen, pursuant to HKEx Listing Rules. An Extraordinary General Meeting (EGM) is expected to be held in due course.
Term and Termination: The exercise period for the Direct Purchase Option will commence on the first day of the month following shareholder approval. It will terminate on the earliest of: (a) Amgen's ownership dropping below 20% due to sales; (b) 60-day advance written notice of termination by either party; or (c) the third anniversary of the commencement date.
Regulatory Status: Additional shares will be issued via private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D, bearing standard restrictive legends.
Investor Verification Checklist
- Confirm the outcome of the upcoming Extraordinary General Meeting (EGM) regarding shareholder approval of the Direct Purchase Option.
- Monitor BeiGene's equity incentive plan issuances to assess potential dilution triggering Amgen's option.
- Review the full text of the Restated Amendment No. 2 (Exhibit 10.1) for detailed covenants and conditions.
- Verify Amgen's current ownership percentage relative to the 20.4% threshold for option exercise.